GlassScriptPhysician profile
Jillian E Stancevic
NPI 1033615786
$4,878.64
in general payments reported to CMS, 2019-2025
23 companies · $759 in 2025
The $759 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,419 · 2022: $1,541 · 2023: $1,002 · 2024: $158 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,818.04 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $775.85 | 2021-2025 | Onpattro, Amvuttra |
| Janssen Pharmaceuticals, INC | $771.12 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $630.43 | 2021-2023 | Jardiance |
| Boston Scientific Corporation | $484.77 | 2021-2025 | Watchman Flx, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $381.48 | 2022-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $259.43 | 2022-2024 | Farxiga |
| Esperion Therapeutics, INC. | $230.27 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $151.78 | 2021-2024 | |
| Bridgebio Pharma, INC. | $148.68 | 2025 | Attruby |
| Scpharmaceuticals INC. | $136.96 | 2023 | |
| Eisai INC. | $135.79 | 2024-2025 | |
| Silk Road Medical, INC. | $129.24 | 2022 | |
| Novo Nordisk INC | $125.00 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $99.95 | 2023 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $95.43 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $94.23 | 2022 | |
| Argenx US, INC. | $47.52 | 2024-2025 | Vyvgart Hytrulo |
| Lundbeck LLC | $42.93 | 2024-2025 | Vyepti |
| Invivyd INC | $36.34 | 2024-2025 | Pemgarda |
| Novartis Pharmaceuticals Corporation | $33.91 | 2023 | |
| Biogen, INC. | $33.19 | 2025 | Tysabri |
| Genentech USA, INC. | $17.99 | 2024 | Ocrevus, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $16.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Stancevic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.